Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex

Ji young Kim, Gayong Shim, Hyun woo Choi, Jooho Park, Seung Woo Chung, Sunil Kim, Kwang Meyung Kim, Ick Chan Kwon, Chan Wha Kim, Sang Yoon Kim, Victor C. Yang, Yu Kyoung Oh, Youngro Byun

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The chemical conjugate of low molecular weight heparin with taurocholate (LHT7) was previously designed to offer anticancer activity while minimizing the anticoagulant activity. In the present study, we found that the systemic administration of LHT7 in nanolipoplex could substantially enhance tumor vasculature targeting and anticancer effects. Moreover, we found that co-delivery of LHT7 with suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in nanolipoplex could provide synergistic antitumor effect. LHT7/SAHA nanolipoplex was formulated by encapsulating SAHA inside cationic liposomes, followed by complexation of negatively charged LHT7 onto the cationic surfaces of SAHA-loaded liposomes (SAHA-L). LHT7/SAHA nanolipoplex was positively charged with a mean diameter of 117.6 nm, and stable in serum. The nanolipoplex form of LHT7 could alter its pharmacokinetics and biodistribution. Compared to the free form of LHT7, LHT7 in the nanolipoplex showed 1.9-fold higher mean residence time, and higher tumor vasculature accumulation after its intravenous administration. LHT7/SAHA nanolipoplex showed highest antitumor efficacy in SCC-bearing mice, compared to LHT7, SAHA-L and sequential co-administration of LHT7 and SAHA-L. Consistent with the enhanced antitumor effect, the reduction of abnormal vessels in the tumor site was also the highest in the LHT7/SAHA nanolipoplex-treated group. These results suggested the potential of LHT7/SAHA nanolipoplex for enhanced tumor vasculature targeting, and the importance of nanolipoplex-mediated co-delivery with a histone deacetylase inhibitor for maximal anticancer effect.

Original languageEnglish
Pages (from-to)4424-4430
Number of pages7
JournalBiomaterials
Volume33
Issue number17
DOIs
Publication statusPublished - 2012 Jun 1

Fingerprint

Taurocholic Acid
Heparin
Tumors
Acids
Neoplasms
Histone Deacetylase Inhibitors
Liposomes
vorinostat
Bearings (structural)
Pharmacokinetics
Low Molecular Weight Heparin
Complexation
Intravenous Administration
Anticoagulants
Molecular weight

Keywords

  • Angiogenesis inhibitor
  • Cationic nanolipoplex
  • Heparin-taurocholate conjugate
  • Histone deacetylase inhibitor
  • Tumor vasculature targeting

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. / Kim, Ji young; Shim, Gayong; Choi, Hyun woo; Park, Jooho; Chung, Seung Woo; Kim, Sunil; Kim, Kwang Meyung; Kwon, Ick Chan; Kim, Chan Wha; Kim, Sang Yoon; Yang, Victor C.; Oh, Yu Kyoung; Byun, Youngro.

In: Biomaterials, Vol. 33, No. 17, 01.06.2012, p. 4424-4430.

Research output: Contribution to journalArticle

Kim, Ji young ; Shim, Gayong ; Choi, Hyun woo ; Park, Jooho ; Chung, Seung Woo ; Kim, Sunil ; Kim, Kwang Meyung ; Kwon, Ick Chan ; Kim, Chan Wha ; Kim, Sang Yoon ; Yang, Victor C. ; Oh, Yu Kyoung ; Byun, Youngro. / Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex. In: Biomaterials. 2012 ; Vol. 33, No. 17. pp. 4424-4430.
@article{37743829b5e94ce2b844ccb3a8dc17fb,
title = "Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex",
abstract = "The chemical conjugate of low molecular weight heparin with taurocholate (LHT7) was previously designed to offer anticancer activity while minimizing the anticoagulant activity. In the present study, we found that the systemic administration of LHT7 in nanolipoplex could substantially enhance tumor vasculature targeting and anticancer effects. Moreover, we found that co-delivery of LHT7 with suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in nanolipoplex could provide synergistic antitumor effect. LHT7/SAHA nanolipoplex was formulated by encapsulating SAHA inside cationic liposomes, followed by complexation of negatively charged LHT7 onto the cationic surfaces of SAHA-loaded liposomes (SAHA-L). LHT7/SAHA nanolipoplex was positively charged with a mean diameter of 117.6 nm, and stable in serum. The nanolipoplex form of LHT7 could alter its pharmacokinetics and biodistribution. Compared to the free form of LHT7, LHT7 in the nanolipoplex showed 1.9-fold higher mean residence time, and higher tumor vasculature accumulation after its intravenous administration. LHT7/SAHA nanolipoplex showed highest antitumor efficacy in SCC-bearing mice, compared to LHT7, SAHA-L and sequential co-administration of LHT7 and SAHA-L. Consistent with the enhanced antitumor effect, the reduction of abnormal vessels in the tumor site was also the highest in the LHT7/SAHA nanolipoplex-treated group. These results suggested the potential of LHT7/SAHA nanolipoplex for enhanced tumor vasculature targeting, and the importance of nanolipoplex-mediated co-delivery with a histone deacetylase inhibitor for maximal anticancer effect.",
keywords = "Angiogenesis inhibitor, Cationic nanolipoplex, Heparin-taurocholate conjugate, Histone deacetylase inhibitor, Tumor vasculature targeting",
author = "Kim, {Ji young} and Gayong Shim and Choi, {Hyun woo} and Jooho Park and Chung, {Seung Woo} and Sunil Kim and Kim, {Kwang Meyung} and Kwon, {Ick Chan} and Kim, {Chan Wha} and Kim, {Sang Yoon} and Yang, {Victor C.} and Oh, {Yu Kyoung} and Youngro Byun",
year = "2012",
month = "6",
day = "1",
doi = "10.1016/j.biomaterials.2012.02.066",
language = "English",
volume = "33",
pages = "4424--4430",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "17",

}

TY - JOUR

T1 - Tumor vasculature targeting following co-delivery of heparin-taurocholate conjugate and suberoylanilide hydroxamic acid using cationic nanolipoplex

AU - Kim, Ji young

AU - Shim, Gayong

AU - Choi, Hyun woo

AU - Park, Jooho

AU - Chung, Seung Woo

AU - Kim, Sunil

AU - Kim, Kwang Meyung

AU - Kwon, Ick Chan

AU - Kim, Chan Wha

AU - Kim, Sang Yoon

AU - Yang, Victor C.

AU - Oh, Yu Kyoung

AU - Byun, Youngro

PY - 2012/6/1

Y1 - 2012/6/1

N2 - The chemical conjugate of low molecular weight heparin with taurocholate (LHT7) was previously designed to offer anticancer activity while minimizing the anticoagulant activity. In the present study, we found that the systemic administration of LHT7 in nanolipoplex could substantially enhance tumor vasculature targeting and anticancer effects. Moreover, we found that co-delivery of LHT7 with suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in nanolipoplex could provide synergistic antitumor effect. LHT7/SAHA nanolipoplex was formulated by encapsulating SAHA inside cationic liposomes, followed by complexation of negatively charged LHT7 onto the cationic surfaces of SAHA-loaded liposomes (SAHA-L). LHT7/SAHA nanolipoplex was positively charged with a mean diameter of 117.6 nm, and stable in serum. The nanolipoplex form of LHT7 could alter its pharmacokinetics and biodistribution. Compared to the free form of LHT7, LHT7 in the nanolipoplex showed 1.9-fold higher mean residence time, and higher tumor vasculature accumulation after its intravenous administration. LHT7/SAHA nanolipoplex showed highest antitumor efficacy in SCC-bearing mice, compared to LHT7, SAHA-L and sequential co-administration of LHT7 and SAHA-L. Consistent with the enhanced antitumor effect, the reduction of abnormal vessels in the tumor site was also the highest in the LHT7/SAHA nanolipoplex-treated group. These results suggested the potential of LHT7/SAHA nanolipoplex for enhanced tumor vasculature targeting, and the importance of nanolipoplex-mediated co-delivery with a histone deacetylase inhibitor for maximal anticancer effect.

AB - The chemical conjugate of low molecular weight heparin with taurocholate (LHT7) was previously designed to offer anticancer activity while minimizing the anticoagulant activity. In the present study, we found that the systemic administration of LHT7 in nanolipoplex could substantially enhance tumor vasculature targeting and anticancer effects. Moreover, we found that co-delivery of LHT7 with suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in nanolipoplex could provide synergistic antitumor effect. LHT7/SAHA nanolipoplex was formulated by encapsulating SAHA inside cationic liposomes, followed by complexation of negatively charged LHT7 onto the cationic surfaces of SAHA-loaded liposomes (SAHA-L). LHT7/SAHA nanolipoplex was positively charged with a mean diameter of 117.6 nm, and stable in serum. The nanolipoplex form of LHT7 could alter its pharmacokinetics and biodistribution. Compared to the free form of LHT7, LHT7 in the nanolipoplex showed 1.9-fold higher mean residence time, and higher tumor vasculature accumulation after its intravenous administration. LHT7/SAHA nanolipoplex showed highest antitumor efficacy in SCC-bearing mice, compared to LHT7, SAHA-L and sequential co-administration of LHT7 and SAHA-L. Consistent with the enhanced antitumor effect, the reduction of abnormal vessels in the tumor site was also the highest in the LHT7/SAHA nanolipoplex-treated group. These results suggested the potential of LHT7/SAHA nanolipoplex for enhanced tumor vasculature targeting, and the importance of nanolipoplex-mediated co-delivery with a histone deacetylase inhibitor for maximal anticancer effect.

KW - Angiogenesis inhibitor

KW - Cationic nanolipoplex

KW - Heparin-taurocholate conjugate

KW - Histone deacetylase inhibitor

KW - Tumor vasculature targeting

UR - http://www.scopus.com/inward/record.url?scp=84862809560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862809560&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2012.02.066

DO - 10.1016/j.biomaterials.2012.02.066

M3 - Article

C2 - 22425551

AN - SCOPUS:84862809560

VL - 33

SP - 4424

EP - 4430

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 17

ER -